Pinealon
Bioregulator peptide with limited clinical evidence
Brief Overview: Pinealon is a short EDR tripeptide discussed for neuroprotection, cognitive aging, and bioregulator concepts. Evidence lens: Most support is preclinical, small, regional, or mechanistic. The guide should not present it as a proven dementia, sleep, DNA-repair, or longevity therapy. How to read this: if you're new, treat Pinealon as experimental. Once you're past the basics, ask whether evidence uses objective cognitive testing, sleep metrics, biomarkers, or simply subjective clarity.
- Pinealon is a synthetic tripeptide often grouped with Khavinson-style peptide bioregulators.
- It is usually discussed in neuro-aging and cognitive-repair contexts rather than as a single-receptor drug.
- Pinealon is a short synthetic tripeptide bioregulator associated with neuro/cognitive and longevity claims. It is low-evidence, not a proven brain-aging therapy.
- Proposed mechanisms include gene-expression modulation, antioxidant effects, peptide bioregulation, and neuronal-protection signaling. These are broad hypotheses with limited direct human validation. The mechanism here is a plausibility map, not proof of a clinical outcome.
- The available evidence is preliminary.
- Claims about DNA repair, dementia improvement, or anti-aging effects need exact sources and do not generalize from cell or animal work.
- Evidence is largely regional, preclinical, or low-volume. Community use is worth including, but those claims are exploratory. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.
Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.
- Protocol 1: Clinical/Oral Trial Protocols [Clinical/Human Trial]; Route: Oral; Dose: Starting Dose: 0.2 mg (2 pills); Max Dose: 0.4 mg (daily); Frequency: Twice daily (BID); Duration: 20 to 30 days; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 2: Common Biohacker Protocols [Community/Biohacker/Anecdotal]; Route: Oral; Dose: Starting Dose: 1.0 mg (1 pill); Max Dose: 2.0 mg (daily); Frequency: Once daily; Timing: Morning or early afternoon; Duration: 20 to 30 days; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Community short cycles exist, but dosing is not based on strong dose-ranging trials. Route and product identity matter. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.
- Time until steady state: not calculable.
- Half-life basis: reliable human PK is not established. Bioregulator effect claims are not plasma steady-state claims.
- Beginner translation: The compound may be discussed as a bioregulator, but the guide cannot honestly assign a blood steady-state time without human PK.Practical interpretation: Track objective cognition, sleep, mood, and adverse effects rather than relying on duration claims.
- As a tripeptide, it likely clears quickly, but proposed gene-expression effects would be downstream. Half-life calculators are not very useful. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.
- Pinealon is sometimes discussed with Epithalon, Semax, Selank, NAD+, or Cerebrolysin, but these combinations are anecdotal. Multiple neuroactive compounds make it harder to identify benefits or side effects.
- Often paired with Epithalon, Vilon, Semax/Selank, or NAD/mitochondrial support. Avoid too many low-evidence longevity compounds at once. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.
- Human safety data are limited.
- Potential issues include headache, sleep disruption, mood changes, injection-site reaction, product contamination, and unpredictable neuroactive effects.
- Pregnancy, breastfeeding, seizure disorders, bipolar disorder, or active neurologic disease require clinician review.
- Short peptide size may reduce some concerns but does not establish long-term safety. Product quality and unknown CNS effects remain relevant. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.
- Use sleep logs, mood logs, standardized cognitive tasks, headache tracking, blood pressure if symptomatic, and adverse-effect review.
- Consumer claims about DNA age or telomeres are not validation.
- Track sleep, mood, cognition tasks, headaches, and general labs if part of a broader longevity protocol. Use baseline and follow-up, not vague impressions. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.
- Pinealon is not FDA-approved for human use and is generally sold as a research chemical or in non-U.S. bioregulator markets.
- Athletes should verify status before use.
- Regional bioregulator use is not U.S. therapeutic approval. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.